Virologic outcomes in early antiretroviral treatment: HPTN 052

References

• Lingappa JR, Hughes JP, Wang RS, et al. Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PLoS ONE. 2010;5:e12598.10.1371/journal.pone.0012598
   PubMed Web of Science ®Google Scholar
• Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med. 2000;342:921–929.10.1056/NEJM200003303421303
   PubMed Web of Science ®Google Scholar
• Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493–505.10.1056/NEJMoa1105243
   PubMed Web of Science ®Google Scholar
• Cohen MS, Chen YQ, McCauley M, et al. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med. 2016;375:830–839.10.1056/NEJMoa1600693
   PubMed Web of Science ®Google Scholar
• Eshleman SH, Hudelson SE, Redd AD, et al. Analysis of genetic linkage of HIV from couples enrolled in the HIV prevention trials network 052 trial. J Infect Dis. 2011;204:1918–1926.10.1093/infdis/jir651
   PubMed Web of Science ®Google Scholar
• Eshleman SH, Hudelson SE, Redd AD, et al. Treatment as prevention: characterization of partner infections in the HIV prevention trials network 052 trial. J Acquir Immune Defic Syndr. 2016;74:112–116.
   Web of Science ®Google Scholar
• Ping LH, Jabara CB, Rodrigo AG, et al. HIV-1 transmission during early antiretroviral therapy: evaluation of two HIV-1 transmission events in the HPTN 052 prevention study. PLoS ONE. 2013;8:e71557.10.1371/journal.pone.0071557
   PubMed Web of Science ®Google Scholar
• Anglemyer A, Rutherford GW, Horvath T, et al. Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane Database Syst Rev. 2013;4:CD009153.
   Google Scholar
• Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010;375:2092–2098.10.1016/S0140-6736(10)60705-2
   PubMed Web of Science ®Google Scholar
• Lu W, Zeng G, Luo J, et al. HIV transmission risk among serodiscordant couples: a retrospective study of former plasma donors in Henan. China. J Acquir Immune Defic Syndr. 2010;55:232–238.
   PubMed Web of Science ®Google Scholar
• Mujugira A, Celum C, Coombs RW, et al. HIV transmission risk persists during the first 6 months of antiretroviral therapy. J Acquir Immune Defic Syndr. 2016;72:579–584.
   PubMed Web of Science ®Google Scholar
• Rodger AJ, Cambiano V, Bruun T, et al. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA. 2016;316:171–181.10.1001/jama.2016.5148
   PubMed Web of Science ®Google Scholar
• Fogel JM, Wang L, Parsons TL, et al. Undisclosed antiretroviral drug use in a multi-national clinical trial (HPTN 052). J Infect Dis. 2013;208:1624–1628.10.1093/infdis/jit390
   PubMed Web of Science ®Google Scholar
• Grinsztejn B, Hosseinipour MC, Ribaudo HJ, et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis. 2014;14:281–290.10.1016/S1473-3099(13)70692-3
   PubMed Web of Science ®Google Scholar
• Phillips AN, Staszewski S, Weber R, et al. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA. 2001;286:2560–2567.10.1001/jama.286.20.2560
   PubMed Web of Science ®Google Scholar
• Mujugira A, Celum C, Tappero JW, et al. Younger age predicts failure to achieve viral suppression and virologic rebound among HIV-1-infected persons in serodiscordant partnerships. AIDS Res Hum Retroviruses. 2016;32:148–154.10.1089/aid.2015.0296
   PubMed Web of Science ®Google Scholar
• Sabin CA, Smith CJ, d’Arminio Monforte A, et al. Response to combination antiretroviral therapy: variation by age. AIDS. 2008;22:1463–1473.
   PubMed Web of Science ®Google Scholar
• Nachega JB, Hislop M, Nguyen H, et al. Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in Southern Africa. J Acquir Immune Defic Syndr. 2009;51:65–71.10.1097/QAI.0b013e318199072e
   PubMed Web of Science ®Google Scholar
• Zanoni BC, Mayer KH. The adolescent and young adult HIV cascade of care in the United States: exaggerated health disparities. AIDS Patient Care STDs. 2014;28:128–135.10.1089/apc.2013.0345
   PubMed Web of Science ®Google Scholar
• Safren SA, Mayer KH, Ou SS, et al. Adherence to early antiretroviral therapy: results from HPTN 052, a Phase III, multinational randomized trial of ART to prevent HIV-1 sexual transmission in serodiscordant couples. J Acquir Immune Defic Syndr. 2015;69:234–240.10.1097/QAI.0000000000000593
   PubMed Web of Science ®Google Scholar
• Paraskevis D, Touloumi G, Bakoyannis G, et al. Effect of HIV type 1 subtype on virological and immunological response to combination antiretroviral therapy: evidence for a more rapid viral suppression for subtype A than subtype B-infected greek individuals. AIDS Res Hum Retroviruses. 2013;29:461–469.10.1089/aid.2012.0143
   PubMed Web of Science ®Google Scholar
• Geretti AM, Harrison L, Green H, et al. Effect of HIV‐1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Clin Infect Dis. 2009;48:1296–1305.10.1086/599387
   PubMed Web of Science ®Google Scholar
• Haubrich RH, Riddler SA, Ribaudo H, et al. Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection. AIDS. 2011;25:2269–2278.10.1097/QAD.0b013e32834d0c20
   PubMed Web of Science ®Google Scholar
• Kuritzkes DR, Ribaudo HJ, Squires KE, et al. Plasma HIV‐1 RNA dynamics in antiretroviral‐naive subjects receiving either triple‐nucleoside or efavirenz‐containing regimens: ACTG A5166s. J Infect Dis. 2007;195:1169–1176.10.1086/522475
   PubMed Web of Science ®Google Scholar
• Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358:2095–2106.10.1056/NEJMoa074609
   PubMed Web of Science ®Google Scholar
• Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr. 2007;46:125–133.10.1097/QAI.0b013e318157131c
   PubMed Web of Science ®Google Scholar
• Murray JM, Emery S, Kelleher AD, et al. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS. 2007;21:2315–2321.10.1097/QAD.0b013e3282f12377
   PubMed Web of Science ®Google Scholar
• Rupérez M, Pou C, Maculuve S, et al. Determinants of virological failure and antiretroviral drug resistance in Mozambique. J Antimicrob Chemother. 2015;70:2639–2647.10.1093/jac/dkv143
   PubMed Web of Science ®Google Scholar
• Beer L, Skarbinski J. Adherence to antiretroviral therapy among HIV-infected adults in the United States. AIDS Educ Prev. 2014;26:521–537.
   PubMed Web of Science ®Google Scholar
• Labhardt ND, Bader J, Ramoeletsi M, et al. Clinical and socio-demographic predictors for virologic failure in rural Southern Africa: preliminary findings from CART-1. J Intl AIDS Soc. 2014;17:19666.
   PubMed Web of Science ®Google Scholar
• Kantor R, Smeaton L, Vardhanabhuti S, et al. Pretreatment HIV drug resistance and HIV-1 subtype C are independently associated with virologic failure: results from the multinational PEARLS (ACTG A5175) clinical trial. Clin Infect Dis. 2015;60:1541–1549.
   PubMed Web of Science ®Google Scholar
• Häggblom A, Svedhem V, Singh K, et al. Virological failure in patients with HIV-1 subtype C receiving antiretroviral therapy: an analysis of a prospective national cohort in Sweden. Lancet HIV. 2016;3:e166–e174.10.1016/S2352-3018(16)00023-0
   PubMed Web of Science ®Google Scholar
• INSIGHT START Study Group, Lundgren JD, Babiker AG, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373:795–807.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2nd ed; 2016. Available from: http://www.who.int/hiv/pub/arv/arv-2016/en/. Accessed June 21, 2016.
   Google Scholar